Clinical Trial Update: Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating desvenlafaxine succinate sustained release (DVS SR) for major depressive disorder has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Desvenlafaxine succinate sustained-release (DVS SR) (desvenlafaxine succinate)

Snippet

Sponsor: Pfizer | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2011-06-06